Menopause Masterclass: HRT Safety, Patch Absorption, Progesterone Intolerance, and Bone Density

Historically, HRT was titrated only to hot flash relief, and measuring estradiol was considered unnecessary because the therapeutic endpoint was symptom resolution. Haver challenges this by emphasizing that bone loss accelerates in perimenopause and continues in postmenopause, and that symptom relief tells you nothing about bone protection. She describes the Glenn‑Newson data showing wide inter‑individual variability in absorption from the same patch dose: 20% of women fail to reach physiologic estradiol levels even on the highest dose. In her own case, she was on the highest‑dose patch and had complete hot flash control, yet her estradiol was 37‑39 pg/mL—far below the bone‑protective threshold. She therefore adjusted her therapy to achieve levels around 60. She couples this with a multi‑pronged bone strategy: heavy resistance training, impact exercises (box jumps), adequate dietary protein and calcium, and vitamin D optimization. This integrated approach has allowed her, a thin woman with a family history of osteoporosis, to maintain the bone density of someone in her mid‑30s.

Haver dismantles the blanket denial of HRT for women with clotting histories. She emphasizes that the contraindication applies only to oral estrogen, not to transdermal or vaginal forms. She points out that many clinicians wrongly tell women with a history of migraines, blood clots, or MTHFR that they can never use hormones. In reality, these women can safely use gels, patches, or especially vaginal estrogen, which has negligible systemic absorption. She also addresses the rare case of severe liver disease, where even transdermal therapy requires expert monitoring because the liver’s ability to metabolize estrogen is compromised. This nuanced guidance opens the door for many women previously excluded from HRT.

Haver introduces Duavee as a solution for two challenging clinical scenarios. First, for women who experience persistent spotting or bleeding on HRT despite progesterone dose increases, Duavee reliably stops the bleeding. She cautions clinicians not to rush to biopsy or hysteroscopy within the first 6 months, as some bleeding is normal, but for those who continue to bleed, Duavee is an elegant option. Second, for women with high breast cancer concern, the SERM provides breast protection while still delivering systemic estrogen benefits. She acknowledges its limitations (no generic, single dose) but wants women to know that this option exists.

Haver begins by normalizing that it is perfectly acceptable not to want sex, quoting Rachel Rubin: 'No one ever died because they didn't have an orgasm.' Only when the loss of desire causes personal distress does she discuss HSDD. She explains the two FDA‑approved non‑hormonal options (Addyi and Vyleesi) but focuses on testosterone as an effective and well‑tolerated option for many. She details the monitoring protocol to avoid virilizing side effects and shares her strong opposition to pellet clinics that push women into supraphysiologic ranges. She underscores that testosterone should be a shared decision, and that women deserve all delivery options, not a single‑formula clinic.

Haver shares her personal story of using progesterone for fertility treatments during residency and experiencing severe dizziness in the operating room. She recognizes that many women feel 'loopy' or profoundly depressed on oral progesterone. The vaginal approach is a simple, affordable workaround using the same gel‑cap pill. She notes that common sense suggests direct absorption to the uterus should be at least as effective as oral for endometrial protection, and her clinical experience supports this. She also mentions other alternatives like progestin‑containing IUDs, CombiPatch, or Duavee for those who need different options.

Haver directly addresses clinicians, urging them not to subject women to unnecessary biopsies, hysteroscopies, or D&Cs within the first months. She shares that the data show a higher rate with transdermal delivery. The management is patience and dose tweaking: lower estrogen or higher progestogen can help. If bleeding persists after half a year and workup is normal, she points to Duavee as a next step. This compassionate stance prevents the common cascade of over‑investigation that traumatizes patients.

Haver differentiates between deficiency (<30) and optimal (60–100). Many labs flag 30 as normal, but that is merely the threshold to prevent rickets/osteomalacia. She routinely checks levels and tailors supplementation, sometimes using prescription strength loading doses. She also stresses getting vitamin D from sunlight is challenging because women rightly protect their skin, necessitating oral supplementation. This is one of the few supplements she considers nearly universal for menopausal women.

Haver references Dr. Abby Smith‑Ryan’s research showing that creatine benefits menopausal women beyond the gym—improving mental health and cognition. She notes that creatine is synergistic with protein intake. She shares her personal protocol: 5 grams daily, doubled on heavy training days or when she is sleep‑deprived or traveling. She advises a slow introduction, starting at 3 grams, to avoid bloating. She is not measuring creatine serum levels but relies on the robust safety and efficacy data.

Haver explains that women with a family history but no personal cancer diagnosis should not be disqualified. She emphasizes that for genetic carriers with high-risk mutations, the decision is more nuanced and requires specialist consultation. She also touches on anatomical conditions like endometriosis, fibroids, and polyps—none of which are automatic contra‑indications—and notes that patients with endometriosis may do well with combined estrogen plus progestin to suppress any residual implants.

Haver references a study by Sarah Glenn and Louise Newson that measured estradiol levels in women on standardized transdermal doses and found wide variability: about 20% were poor absorbers who never reached physiologic levels even on the highest dose patches. She explains that while hot flashes may resolve at suboptimal estradiol levels, bone loss continues. She herself tested at 37-39 pg/mL on the maximum patch, well below the bone protective threshold, so she adjusted her therapy. She stresses that hormone therapy works synergistically with heavy resistance training, adequate protein, calcium‑rich foods, vitamin D, and impact exercises like box jumps to maintain bone density. She now has the bone density of a 35‑year‑old despite having the typical thin, Caucasian phenotype that predisposes to osteoporosis.

She explains that in an untreated woman, a spontaneous total testosterone above 90‑100 ng/dL obligates a thorough investigation for an androgen‑producing tumor. Pushing a woman on therapy over 200, therefore, is medically indefensible. She urges women to avoid clinics that refuse to offer oral, transdermal, or other options, and insists that therapy must stay within physiologic ranges (<100 ng/dL for most). She also notes that irreversible side effects such as voice deepening can occur at high levels, which is especially harmful for singers or voice professionals.

She explains that elevated ACE scores correlate strongly with later‑life chronic disease and earlier mortality. For women specifically, the burden of carrying unresolved trauma leads to higher cardiovascular risk, which shortens healthspan. She calls for immediate action to protect children from abuse and for society to stop shielding perpetrators. She also offers hope: counseling and trauma‑informed therapy can mitigate these risks. Resources for finding therapists will be included in the show notes.